CYTOSORBENTS CORP (CTSO) Stock Price, Quote, News and Overview
NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD
CTSO Quote, Performance and Key Statistics
NASDAQ:CTSO (2/20/2025, 8:08:57 PM)
1.15
-0.07 (-5.74%)
The current stock price of CTSO is 1.15 USD. In the past month the price increased by 12.75%. In the past year, price increased by 17.35%.
CTSO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.52 | 230.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 82.75 | 216.34B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.98 | 155.28B | ||
| SYK | STRYKER CORP | 31.7 | 147.31B | ||
| MDT | MEDTRONIC PLC | 16.47 | 112.76B | ||
| BDX | BECTON DICKINSON AND CO | 16.39 | 65.45B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.52 | 44.06B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.51 | 42.07B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.08B | ||
| DXCM | DEXCOM INC | 54.15 | 34.90B | ||
| RMD | RESMED INC | 26.33 | 34.19B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.14 | 23.53B |
Related stock screener links
About CTSO
Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 186 full-time employees. The company went IPO on 2005-06-17. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Company Info
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852 US
CEO: Phillip P. Chan
Employees: 186
Company Website: https://cytosorbents.com/
Investor Relations: https://cytosorbents.com/investor-relations/overview
Phone: 19733298885
CYTOSORBENTS CORP / CTSO FAQ
What is the stock price of CYTOSORBENTS CORP today?
The current stock price of CTSO is 1.15 USD. The price decreased by -5.74% in the last trading session.
What is the ticker symbol for CYTOSORBENTS CORP stock?
The exchange symbol of CYTOSORBENTS CORP is CTSO and it is listed on the Nasdaq exchange.
On which exchange is CTSO stock listed?
CTSO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTOSORBENTS CORP stock?
8 analysts have analysed CTSO and the average price target is 7.14 USD. This implies a price increase of 520.87% is expected in the next year compared to the current price of 1.15. Check the CYTOSORBENTS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTOSORBENTS CORP worth?
CYTOSORBENTS CORP (CTSO) has a market capitalization of 63.05M USD. This makes CTSO a Micro Cap stock.
How many employees does CYTOSORBENTS CORP have?
CYTOSORBENTS CORP (CTSO) currently has 186 employees.
What are the support and resistance levels for CYTOSORBENTS CORP (CTSO) stock?
CYTOSORBENTS CORP (CTSO) has a support level at 0.98 and a resistance level at 1.3. Check the full technical report for a detailed analysis of CTSO support and resistance levels.
Is CYTOSORBENTS CORP (CTSO) expected to grow?
The Revenue of CYTOSORBENTS CORP (CTSO) is expected to grow by 5.35% in the next year. Check the estimates tab for more information on the CTSO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTOSORBENTS CORP (CTSO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTSO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTSO, evaluating the profitability, health, valuation and growth aspects
- CYTOSORBENTS CORP (CTSO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTOSORBENTS CORP (CTSO) Sales and EPS estimates to see what analysts future expectations are.
- CYTOSORBENTS CORP (CTSO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTOSORBENTS CORP (CTSO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTOSORBENTS CORP (CTSO) Stock Chart to make your own analysis
- CYTOSORBENTS CORP (CTSO) Latest news and press-releases to stay up to date.
Does CYTOSORBENTS CORP (CTSO) stock pay dividends?
CTSO does not pay a dividend.
When does CYTOSORBENTS CORP (CTSO) report earnings?
CYTOSORBENTS CORP (CTSO) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of CYTOSORBENTS CORP (CTSO)?
CYTOSORBENTS CORP (CTSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the Short Interest ratio of CYTOSORBENTS CORP (CTSO) stock?
The outstanding short interest for CYTOSORBENTS CORP (CTSO) is 3.9% of its float. Check the ownership tab for more information on the CTSO short interest.
CTSO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTSO. When comparing the yearly performance of all stocks, CTSO is one of the better performing stocks in the market, outperforming 85.01% of all stocks.
CTSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTSO. Both the profitability and financial health of CTSO have multiple concerns.
CTSO Financial Highlights
Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 31.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.06% | ||
| ROE | -143.63% | ||
| Debt/Equity | 1.06 |
CTSO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CTSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 53.45% and a revenue growth 5.35% for CTSO